Promethera Biosciences, a Belgian biotechnology company developing a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, has named Dr John Tchelingerian chair of its board of directors. Dr Tchelingerian is a serial entrepreneur and a private investor. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos.

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

An increase in demand from small- and medium-sized drug development companies for non-clinical development support has led to one young CRO, Leads to Development (L2D), opening new two new offices alongside its Paris, France base.